Inhibitor Therapeutics, Inc.
INTI
$0.06
$0.0120.00%
| Weiss Ratings | INTI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | INTI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | INTI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.84 | |||
| Price History | INTI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -14.29% | |||
| 30-Day Total Return | -8.95% | |||
| 60-Day Total Return | 0.00% | |||
| 90-Day Total Return | -27.18% | |||
| Year to Date Total Return | -7.69% | |||
| 1-Year Total Return | -12.15% | |||
| 2-Year Total Return | -14.29% | |||
| 3-Year Total Return | -25.09% | |||
| 5-Year Total Return | -9.09% | |||
| 52-Week High % Change | -56.40% | |||
| 52-Week Low % Change | 45.99% | |||
| Price | INTI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.14 | |||
| 52-Week Low Price | $0.04 | |||
| 52-Week Low Price (Date) | Apr 01, 2025 | |||
| 52-Week High Price (Date) | May 13, 2024 | |||
| Valuation | INTI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 10.34M | |||
| Enterprise Value | 4.73M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.02 | |||
| Earnings Per Share Growth | 10.23% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 5.22 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.06 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -1.29 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | INTI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 172.32M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | INTI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 813-864-2562 | |||
| Address | 900 West Platt St Tampa, FL 33606-2173 | |||
| Website | inhibitortx.com | |||
| Country | United States | |||
| Year Founded | 1992 | |||
| Profitability | INTI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | INTI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -31.22% | |||
| Return on Equity | -- | |||
| Income Statement | INTI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -3.66M | |||
| Net Income (TTM) | -3.34M | |||
| Net Income Avl. to Common (TTM) | -3.34M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -21.80% | |||
| EPS Diluted (TTM) | -0.02 | |||
| EPS Diluted Growth (Q YOY) | -22.06% | |||
| Balance Sheet | INTI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 5.61M | |||
| Cash Per Share (Q) | $0.03 | |||
| Total Current Assets (Q) | 5.69M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.99M | |||
| Current Ratio (Q) | 8.025 | |||
| Book Value Per Share (Q) | $0.01 | |||
| Total Assets (Q) | 5.69M | |||
| Total Current Liabilities (Q) | 709.60K | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 3.71M | |||
| Total Common Equity (Q) | 1.99M | |||
| Cash Flow | INTI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | -- | |||
| Net Change in Cash (TTM) | -3.23M | |||
| Levered Free Cash Flow (TTM) | -2.18M | |||
| Cash from Operations (TTM) | -3.23M | |||
